TriEn Bio Plans Major Focus on Next-Gen Bio-Materials in 2026

TriEn Bio announced on the 10th that it will concentrate its research and business strategies in the second half of the year on PDRN, exosomes, and hybrid oleosomes, targeting advanced bio-materials in the global cosmetics market.

The shift observed at in-cosmetics Korea 2026 highlights a clear transformation in the cosmetics raw material sector, where global brands and buyers are increasingly demanding not just new concepts, but scientifically-backed effectiveness demonstrated through data and distinct bio-technologies. This evolving landscape indicates a strategic pivot for suppliers who must adapt to these higher expectations.

Focusing heavily on plant-derived PDRN, which has emerged as a pivotal bio-material in the fields of regeneration and anti-aging, TriEn Bio is responding to market demands for products that not only contain PDRN but also convey transparency regarding the material's origin, production technology, quality control, and efficacy validation. This proactive stance highlights a business model shift from mere ingredient provision to a comprehensive strategy encompassing safety, sustainability, and verified performance, thereby building long-term trust with global customers.

Exosomes represent another critical area of development for TriEn Bio. Leveraging intercellular communication mechanisms, plant-derived exosomes are recognized for their eco-friendliness and scalability, allowing for tailored applications that enhance customer product concepts. This bespoke customization signifies a unique market positioning that caters to the rising trend of personalized skincare, indicating an evolution in buyer-supplier dynamics.

Notably, the hybrid oleosome technology, showcased for the first time at the exhibition, is a distinctive delivery system utilizing natural oil storage structures found in plants. This innovative approach aligns with market expectations for safety and stability in ingredient delivery, offering TriEn Bio a competitive edge in both functionality and scalability.

The company aims to integrate bio-technology with delivery system advancements, setting its sights on high-value platforms that enable effective component delivery. TriEn Bio's commitment to scientific validation from the early stages of development, including mechanism research and human applicability testing, is indicative of its strategy to establish itself as a trusted tech-centric enterprise in the global market.

As consumer preferences increasingly lean toward scientifically substantiated efficacy over 'natural' ingredient sourcing alone, this trend offers a significant opportunity for the domestic cosmetics raw materials industry. The lesson learned from in-cosmetics Korea 2026 is that industry competitiveness will pivot on technical sophistication and validated data, rather than superficial ingredient novelty.